Less Ads, More Data, More Tools Register for FREE

Pin to quick picksTrufin Plc Regulatory News (TRU)

Share Price Information for Trufin Plc (TRU)

Share Price is delayed by 15 minutes
Get Live Data
134.00    -1.00 (-0.75%)
Bid:
133.00
Ask:
135.00
Spread: 2.00 (1.504%)
Market Cap: £125.29m
TRU Live PriceLast checked at - London Stock Exchange

Intraday Trufin Plc Share Chart

Trading Statement

6 Jan 2025 07:00

RNS Number : 1636S
TruFin PLC
06 January 2025
 

6 January 2025

 

TruFin plc("TruFin" or the "Group")

 

Trading Update

 

TruFin is pleased to announce that it expects its adjusted profit before tax1 ("PBT") to be significantly ahead of market expectations resulting in its first full year profit - a year earlier than forecast. For the 12 months ended 31 December 2024, PBT is now expected to be more than £0.5m (FY23: £(6.6)m) with adjusted EBITDA1 also expected to be significantly ahead of prior expectations at more than £7.0m, representing a year-on-year improvement in excess of £10m (FY23: £(3.5)m).

 

Group revenue is expected to be approximately £54.0m. This represents growth in excess of 197% (FY23: £18.1m).

 

The significantly better than expected financial performance has been driven by exceptional year-end performances from Balatro and Abiotic Factor - two of Playstack Limited's ("Playstack") games launched during 2024. Balatro's recent award wins in three categories at the Game Awards: 'Best Independent Game', 'Best Mobile Game' and 'Best Debut Indie Game', helped to significantly boost sales of the game during December.

 

Oxygen Finance Group Limited ("Oxygen") grew revenues with metronomic consistency in 2024, resulting in growth of 21% to no less than £7.5m (FY23: £6.2m). EBITDA grew 65% at no less than £2.1m (FY23: £1.3m). With four new Early Payment ("EP") client wins during 2024 and all four EP clients up for renewal during 2024 contracting for further five year terms, Oxygen ended the year with a record 62 EP clients.

 

Satago Financial Solutions Limited ("Satago") aggressively realigned its cost base during 2024 and is in advanced talks with several Tier-1 Banks and other potential clients. Having lost its contract with a Tier-1 Bank in July 2024, revenues for 2024 are expected to be no less than £2.4m (FY23: £3.8m). Loss before tax is expected to be no more than £(4.9)m (FY23: £(4.2)m). Satago has a fully costed and funded plan to achieve cash flow breakeven in the next 18 months.

 

Cash at year end is no less than £14.0m, of which unrestricted cash is no less than £12.5m. The Group has had an exceptional year and remains focused on realising value for shareholders.

 

James van den Bergh, Chief Executive Officer, commented:

 

"What a year for the Group. A year of many firsts.

This is the first time we have grown revenues by more than 190%. It is the first year we have recorded an EBITDA profit and the first year we have achieved a profit before tax - a year ahead of schedule.

Most importantly our newly minted profitability status is not a one off. Although we expect 2025 to be a year of consolidation, we will maintain our disciplined approach to allocating internal resources and expect the Group to grow all the profitability lines in 2025 and beyond.

After years of considered investment and planning, Playstack has come of age. The standout financial achievements this year are the remarkable revenue growth of over 440% with an exceptional EBITDA growth of over 2,000%.

These achievements would not have been possible without our extremely disciplined and careful approach to building a robust and scalable games publisher.

The success of Balatro should not be underestimated and it has been a joy to watch it build throughout the year. However, it is important to also praise the team for the exceptional performances of Abiotic Factor and The Rise of the Golden Idol. Success breeds success and with eight game releases due in 2025 and a growing pipeline of game releases for 2026, we are closer than ever to monetising shareholder value from Playstack.

Following Vicki Sloane's appointment as Chief Executive Officer of Oxygen it is very pleasing to see her team deliver new highs across the board. Notably, this is the first year that shareholders have enjoyed the benefits of Oxygen's inherent operational gearing. With more than 82% of the next five years' Early Payment revenues already contracted, shareholders have much to look forward to. 

Satago's loss of a Tier-1 Bank contract in July 2024 was an enormous shock. However, the team have realigned the cost base and are poised for a year of growth, with a clear business plan to achieve cash breakeven within 18 months. We are focused on rebuilding shareholder value and the recent share recapitalisation at Satago is the first step to achieving that.

I look forward to providing a more detailed update during TruFin's annual results statement. In the meantime, I would like to again thank our shareholders for their ongoing support. This has been an exceptional year, and it is safe to say the Group has never been better positioned to deliver further shareholder value."

Notes

1 profit or loss adjusted to remove share-based payment charges

 

 

The information contained within this Announcement is deemed by the Company to constitute inside information as stipulated under the Market Abuse Regulation (EU) No.596/2014 as amended by The Market Abuse (Amendment) (EU Exit) Regulations 2019. By the publication of this Announcement via a Regulatory Information Service, this inside information is now considered to be in the public domain. The person responsible for arranging for the release of this Announcement on behalf of the Company is Pav Subramaniam.

For further information, please contact:

TruFin plcJames van den Bergh, Chief Executive OfficerKam Bansil, Investor Relations

0203 743 134007779 229508

Liberum Capital Limited (Nominated Adviser and Corporate broker)Chris ClarkeEdward Thomas

 

0203 100 2000

 

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
 
END
 
 
TSTDZGGMGKZGKZZ
Date   Source Headline
4th Dec 20197:00 amRNSProposed Tender Offer and Trading Update
8th Nov 20197:00 amRNSQ3 Trading Update
26th Sep 20194:33 pmRNSResults of Written Resolutions
13th Sep 20193:55 pmRNSStatement Regarding Closure of Arrowgrass
11th Sep 20194:21 pmRNSDirector/PDMR Shareholding
11th Sep 20197:00 amRNS2019 Interim Results and Company Updates
29th Jul 20197:00 amRNSRestructuring and Update
5th Jun 20197:00 amRNSResult of Tender Offer
4th Jun 20191:19 pmRNSResult of AGM
17th May 20197:00 amRNSNotice of Tender Offer and AGM
9th May 20197:00 amRNSDemerger Effective And DFC Holdings Admission
7th May 201911:46 amRNSGeneral Meeting Results & Completion Of Zopa Sale
3rd May 20195:30 pmRNSTruFin
24th Apr 20193:59 pmRNSDirector/PDMR Shareholding
17th Apr 20196:20 pmRNSResult of Placing
17th Apr 20192:44 pmRNSStrategic Update, Demerger of DFC and Zopa Sale
17th Apr 20192:41 pmRNSFinal Results for the year ended 31 December 2018
22nd Feb 201911:17 amRNSVesting of Share Incentive/Options for PDMRs
7th Dec 20184:05 pmRNSProgress Update
4th Dec 20187:00 amRNSZopa Banking Licence
29th Nov 20187:01 amRNSStrategy/Company/Ops Update
29th Nov 20187:00 amRNSChange of Adviser
14th Sep 20189:04 amRNSDirector/PDMR Shareholding
13th Sep 20187:00 amRNSHalf-year Report
6th Aug 20186:29 pmRNSAcquisition of Porge Ltd by Oxygen Finance Group
3rd Aug 20187:00 amRNSZopa Fundraising
13th Jul 20185:39 pmRNSDirector/PDMR Shareholding
13th Jul 20185:26 pmRNSDirector/PDMR Shareholding
19th Jun 201812:17 pmRNSResult of AGM
1st Jun 20186:30 pmRNSHolding(s) in Company
1st Jun 20184:00 pmRNSPosting of Annual Report and Notice of AGM
30th May 20187:00 amRNSDirector/PDMR Shareholding
30th May 20187:00 amRNSDirector/PDMR Shareholding
16th May 20187:00 amRNSFinal Results for the year ended 31 December 2017
23rd Feb 201810:59 amRNSDirector/PDMR Shareholding
21st Feb 20187:00 amRNSFirst Day of Dealings

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.